Epigenetic biomarker discovery applied to diagnosis, monitoring and prognosis of diseases associated with aberrant gene expression
In this interview, EpigenomicsNet is in discussion with Dr Alexandre Akoulitchev, Chief Scientific Officer at Oxford BioDynamics (UK). Dr Akoulitchev joins us to tell us about the work going on at Oxford BioDynamics, with a focus on the biomarker discovery platform EpiSwitch™, including a brief overview of how it works and its main advantages, before concluding with a brief look at the current and upcoming projects at Oxford BioDynamics.
Please sign in or register for FREE
Sign in to EpigenomicsNet
Register to EpigenomicsNet – the epigenetics and epigenomics network
EpigenomicsNet is a communal space where industry and academic professionals can come together to discuss the latest research and developments, share thoughts and opinions, and build valuable international relationships.